| Literature DB >> 32681866 |
Yanyu Hu1, Yingying Chen1, Yixiong Zheng1, Ciping You1, Jing Tan2, Lan Hu2, Zhenqing Zhang1, Lijun Ding3.
Abstract
OBJECTIVE: To evaluate the mental health status of hospitalized patients with coronavirus disease 2019 (COVID-19) and to explore the related factors.Entities:
Keywords: COVID-19; Hospitalization; Inflammatory markers; Mental health; Patients
Mesh:
Year: 2020 PMID: 32681866 PMCID: PMC7362867 DOI: 10.1016/j.bbi.2020.07.016
Source DB: PubMed Journal: Brain Behav Immun ISSN: 0889-1591 Impact factor: 7.217
Demographic and clinical characteristics of total cohort and different subgroups.
| Total sample | PHQ-9 ≥ 5N = 39 | PHQ-9 < 5N = 46 | P value | GAD-7 ≥ 5N = 33 | GAD-7 < 5N = 52 | P value | ISI ≥ 8N = 46 | ISI < 8N = 39 | P value | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assessment type(%) | ||||||||||
| online | 56.5% | 64.1% | 50.0% | 0.272 | 60.6% | 53.8 | 0.655 | 45.9% | 54.1% | 0.197 |
| paper | 44.5% | 35.9% | 50.0% | 39.4% | 46.2% | 37.0% | 51.3% | |||
| Female(%) | 49.4% | 59.0% | 41.3% | 0.130 | 63.6% | 40.4% | 0.046 | 60.9% | 35.9% | 0.030 |
| Age(year) | 48.8 ± 14.3 | 48.5 ± 14.1 | 49.2 ± 14.7 | 0.810 | 49.3 ± 15.2 | 48.6 ± 13.9 | 0.838 | 49.61 ± 14.7 | 48.0 ± 14.0 | 0.609 |
| Marital status(%) | ||||||||||
| single | 8.2% | 5.1% | 10.0% | 0.240 | 6.1% | 9.6% | 0.921 | 2.2% | 15.4% | 0.145 |
| married | 85.9% | 87.2% | 84.8% | 87.9% | 84.6% | 91.3% | 79.5% | |||
| divorced | 2.4% | 2.6% | 4.3% | 3.0% | 3.8% | 4.3% | 2.6% | |||
| widowed | 3.5% | 5.1% | 0.0% | 3.0% | 1.9% | 2.2% | 2.6% | |||
| Educational level(%) | ||||||||||
| ≥High school | 55.3% | 61.1% | 50.5% | 0.382 | 63.3% | 50.0% | 0.266 | 54.3% | 56.4% | 0.849 |
| <High school | 44.7% | 38.9% | 50.0% | 36.7% | 50.0% | 45.7% | 43.6% | |||
| Disease duration (day) | 32.4 ± 19.6 | 37.4 ± 18.7 | 28.3 ± 19.7 | 0.033 | 37.9 ± 18.9 | 28.9 ± 19.5 | 0.039 | 35.4 ± 18.2 | 29.0 ± 21.0 | 0.141 |
| Hospital stay(day) | 5.7(4.0,8.5) | 7.0(4.0,10.0) | 5.6(3.7,7.2) | 0.139 | 7.0(4.6,10.0) | 5.7(3.7,7.0) | 0.019 | 7.0(4.0,10.9) | 5.6 (4.0,7.0) | 0.040 |
| Oxygen therapy(%) | 49.4% | 61.5% | 39.1% | 0.051 | 60.6% | 42.3% | 0.122 | 52.2% | 46.2% | 0.665 |
Severity categories of depression, anxiety, and insomnia.
| Severity | PHQ-9 depression symptom | GAD-7 Anxiety symptom | ISI Insomnia symptom | |||
|---|---|---|---|---|---|---|
| n | Percent | n | Percent | n | Percent | |
| Normal | 46 | 54.1% | 52 | 61.2% | 39 | 45.9% |
| Mild | 18 | 21.2% | 19 | 22.4% | 28 | 32.9% |
| Moderate | 13 | 15.3% | 10 | 11.8% | 15 | 17.6% |
| Severe | 8 | 9.4% | 4 | 4.7% | 3 | 3.5% |
Abbreviations: PHQ-9: 9-item Patient Health Questionnaire; GAD-7: 7-item Generalized Anxiety Disorder; ISI:Insomnia Severity Index.
Questionnaire results of total cohort and different subgroups.
| Total sample | PHQ-9 ≥ 5N = 39 | PHQ-9 < 5N = 46 | P value | GAD-7 ≥ 5N = 33 | GAD-7 < 5N = 52 | P value | ISI ≥ 8N = 46 | ISI < 8N = 39 | P value | |
|---|---|---|---|---|---|---|---|---|---|---|
| PHQ-9 score | 6.1 ± 5.9 | 11.2 ± 5.5 | 1.6 ± 1.5 | <0.001 | 11.1 ± 5.5 | 2.9 ± 3.8 | <0.001 | 9.3 ± 6.3 | 2.3 ± 2.6 | <0.001 |
| GAD-7 score | 4.7 ± 4.6 | 8.4 ± 4.8 | 1.5 ± 1.9 | <0.001 | 9.8 ± 4.0 | 1.4 ± 1.4 | <0.001 | 7.5 ± 5.0 | 1.4 ± 1.8 | <0.001 |
| ISI score | 9.1 ± 6.8 | 13.3 ± 6.3 | 5.5 ± 4.9 | <0.001 | 14.7 ± 5.5 | 5.5 ± 4.9 | <0.001 | 14.1 ± 5.0 | 3.1 ± 2.5 | <0.001 |
| Self-perceived illness severity | ||||||||||
| Less severe (1 score) | 50.6% | 30.8% | 67.4% | 0.001 | 37.0% | 66.7% | 0.049 | 24.2% | 67.3% | 0.001 |
| Normal (2 score) | 30.6% | 43.6% | 19.6% | 39.1% | 20.5% | 42.4% | 23.1% | |||
| Severe (3 score) | 12.9% | 12.8% | 13.0% | 17.4% | 7.7% | 21.2% | 7.7% | |||
| Very severe (4 score) | 5.9% | 12.8% | 0.0% | 6.5% | 5.1% | 12.1% | 1.9% |
Levels of inflammatory markers in different subgroups.
| Missing Data | PHQ-9 ≥ 5 | PHQ-9 < 5 | P value | GAD-7 ≥ 5 | GAD-7 < 5 | P value | ISI ≥ 8 | ISI < 8 | P value | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytokines | ||||||||||
| IL-1β(pg/mL) | 15 | 2.5(2.5,6.0) | 2.5(2.5,2.5) | 0.080 | 2.5(2.5,6.2) | 2.5(2.5,2.5) | 0.045 | 2.5(2.5,5.6) | 2.5(2.5,2.5) | 0.274 |
| IL-6 (pg/mL) | 15 | 2.2(0.8,5.5) | 2.1(0.8,3.8) | 0.894 | 2.3(0.8,5.6) | 2.0(0.8,3.6) | 0.678 | 1.9(0.8,4.2) | 2.4(1.5,3.8) | 0.333 |
| IL-8 (pg/mL) | 15 | 5.7(0.8,10.9) | 8.8(6.0,12.9) | 0.660 | 7.3(5.4,11.4) | 9.2(6.1,12.0) | 0.413 | 7.6(5.2,11.6) | 9.3(6.5,11.6) | 0.444 |
| IL-10 (pg/mL) | 15 | 2.5(2.5,2.5) | 2.5(2.5,4.9) | 0.442 | 2.5(2.5,2.5) | 2.5(2.5,4.0) | 0.581 | 2.5(2.5,2.5) | 2.5(2.5,5.8) | 0.039 |
| TNF-α(pg/mL) | 15 | 7.3(6.1,9.3) | 7.4(5.5,9.7) | 0.891 | 7.2(6.3,8.6) | 7.8(5.4,9.9) | 0.458 | 7.0(5.8,8.7) | 8.0(5.4,10.2) | 0.180 |
| Hs-CRP (mg/L) | 15 | 1.0(0.5,2.6) | 1.2(0.6,2.7) | 0.417 | 0.9(0.3,2.0) | 0.8(0.6,2.8) | 0.119 | 1.0(0.3,2.0) | 1.4(0.6,2.8) | 0.085 |
| Blood cell counts | ||||||||||
| White blood cell (*10^9/L) | 15 | 6.5 ± 2.6 | 6.0 ± 1.7 | 0.357 | 6.5 ± 2.71 | 6.1 ± 1.7 | 0.427 | 6.2 ± 2.4 | 6.3 ± 1.8 | 0.816 |
| Neutrophil (*10^9/L) | 15 | 4.1 ± 2.4 | 3.4 ± 1.1 | 0.073 | 4.2 ± 2.6 | 3.4 ± 1.2 | 0.146 | 3.8 ± 2.2 | 3.5 ± 1.3 | 0.450 |
| Lymphocyte (*10^9/L) | 15 | 1.7 ± 0.4 | 1.9 ± 0.7 | 0.099 | 1.6 ± 0.4 | 1.9 ± 0.7 | 0.015 | 1.6 ± 0.4 | 2.0 ± 0.7 | 0.010 |
| NLR | 15 | 2.0 (1.4,2.9) | 1.7(1.2,2.3) | 0.141 | 2.1(1.5,3.2) | 1.7(1.3,2.2) | 0.049 | 2.1(1.4,2.8) | 1.6(1.2,2.2) | 0.070 |
Abbreviations: IL:interleukin; TNF-α: tumor necrosis factor-α; hsCRP: high-sensitivity C-reactive protein; NLR: neutrophil to lymphocyte ratio
Correlations between study variables.
| Hospital stay | IL-1β | NLR | self-perceived illness severity | ISI | GAD-7 | PHQ-9 | |
|---|---|---|---|---|---|---|---|
| Disease duration | 0.07 | −0.05 | 0.11 | 0.37** | 0.13 | 0.17 | 0.25* |
| Hospital stay | – | 0.12 | 0.10 | 0.27* | 0.19 | 0.22* | 0.13 |
| IL-1β | – | 0.55** | 0.32* | 0.32** | 0.46*** | 0.50*** | |
| NLR | – | 0.43*** | 0.22 | 0.30* | 0.36** | ||
| self-perceived illness severity | – | 0.29** | 0.44** | 0.46** | |||
| ISI | – | 0.75** | 0.70** | ||||
| GAD-7 | – | 0.80** |
Notes: * p < 0.05 ,** p < 0.01,***p < 0.001.
Regression models of Self-perceived illness severity, ISI score, GAD-7 score, and PHQ-9 score.
| Self-perceived illness severity | ISI | GAD-7 | PHQ-9 | ||||
|---|---|---|---|---|---|---|---|
| Variable | β | Variable | β | Variable | β | Variable | β |
| R2 = 0.20** | R2 = 0.47** | Step1:R2 = 0.30** | Step1:R2 = 0.42*** | ||||
| Sex# | −0.17 | Sex# | 0.24* | Sex# | 0.25* | Sex# | 0.26* |
| Oxygen therapy | 0.01 | IL-1β | 0.25* | Hospital stay | 0.18 | Disease duration | 0.31** |
| Disease duration | 0.32** | Self-perceived illness severity | 0.28* | IL-1β | 0.43** | IL-1β | 0.49*** |
| Hospital stay | 0.20 | NLR | 0.07 | NLR | 0.09 | ||
| IL-1β | 0.17 | Step2:R2 = 0.46** | Step2:R2 = 0.54*** | ||||
| NLR | 0.27* | Sex# | 0.34*** | Sex# | 0.33** | ||
| IL-1β | 0.35** | Disease duration | 0.17 | ||||
| Hospital stay | 0.05 | IL-1β | 0.42*** | ||||
| Self-perceivedillness severity | 0.51*** | Self-perceived illness severity | 0.41*** | ||||
| NLR | −0.08 | NLR | −0.02 | ||||
Notes:* p < 0.05 ,** p < 0.01,***p < 0.001; #:male sex = 1, female sex = 2.
Fig. 1The SEM shows the relationships between sex, disease duration, self-perceived illness severity, inflammatory markers and mental health. Abbreviations: ISI: Insomnia Severity Index; PHQ-9: 9-item Patient Health Questionnaire; GAD-7: 7-item Generalized Anxiety Disorder. Note: *p < 0.05, **p < 0.01, ***p < 0.001.
Direct and indirect effects in SEM.
| Direct or indirect effect of pathway | Standardized path coefficient | S.E | P value |
|---|---|---|---|
| Sex → mental health | 0.313 | 0.082 | <0.001 |
| Self-perceived illness severity → mental health | 0.411 | 0.093 | <0.001 |
| Inflammatory markers → mental health | 0.358 | 0.116 | 0.002 |
| Disease duration → Self-perceived illness severity | 0.396 | 0.088 | <0.001 |
| Inflammatory markers → Self-perceived illness severity | 0.245 | 0.098 | 0.012 |
| Disease duration → Self-perceived illness severity → mental health | 0.163 | 0.055 | 0.003 |
| Inflammatory markers → Self-perceived illness severity → mental health | 0.101 | 0.042 | 0.016 |